

San Francisco EMS Agency  
Emergency Medical Services Advisory Committee  
August 2, 2023

## Summary of Proposed Policy & Protocol Revisions

Drafts of the policies and protocols listed can be found below or attached to this revision summary. For existing documents that are being revised, changes mentioned in the Description of Updates will be highlighted in yellow.

SECTION	Type	DESCRIPTION OF UPDATES
4001a Vehicle Equipment and Supply List	Policy	<ul style="list-style-type: none"> <li>Added 2 bougie devices per ALS supervisor vehicle to the equipment list</li> </ul>
4050 Death in Field	Policy	<ul style="list-style-type: none"> <li>Removed word: Liver</li> <li>Added word: Lungs</li> </ul>
5000 Destination	Policy	<ul style="list-style-type: none"> <li>Patients detained or under arrest may be transported to any Receiving Facility</li> <li>Patients who are incarcerated continue to be transported to ZSFG</li> <li>Minor grammatical and formatting changes</li> </ul>
5020 Diversion	Policy	<ul style="list-style-type: none"> <li>Patients detained or under arrest may be transported to any Receiving Facility</li> <li>Patients who are incarcerated continue to be transported to ZSFG</li> <li>Minor grammatical and formatting changes</li> </ul>
2.04 Cardiac Arrest	Protocol	<ul style="list-style-type: none"> <li>Moved alternate vector defibrillation to earlier in the treatment of refractory ventricular fibrillation</li> <li>Added checking blood glucose and correcting under “H’s and T’s” for potential correction of non-shockable rhythms</li> <li>Added considering opiate overdose and the use of naloxone under toxin portion of “H’s and T’s”</li> <li>Added heads-up CPR position of the gurney if transporting a patient with ongoing chest compressions</li> </ul>
2.08 Dysrhythmia: Tachycardia	Protocol	<ul style="list-style-type: none"> <li>Morphine removed from treatment of unstable tachycardia</li> </ul>
7.02 Oral Endotracheal Intubation	Protocol	<ul style="list-style-type: none"> <li>Added high flow oxygen via nasal cannula to intubation procedure</li> <li>Added the recommended use of a bougie device for patients with inability to visualize the glottis</li> </ul>
13.1 Adenosine (Adenocard)	Protocol	<ul style="list-style-type: none"> <li>Clarified language re: use of adenosine as substitute for CV or if CV fails</li> <li>Clarified preferred IV route (at or proximal to antecubital fossa)</li> </ul>
13.1 Atropine Sulfate	Protocol	<ul style="list-style-type: none"> <li>Added clarifying language to adult and pediatric dosing re: Nerve agent exposure</li> </ul>
13.1 Diphenhydramine (Benadryl)	Protocol	<ul style="list-style-type: none"> <li>Clarified language re: action of medication</li> <li>Changed pregnancy from contraindication to relative contraindication</li> </ul>

		<ul style="list-style-type: none"> <li>• Added potentiation of other CNS depressants to potential side effects</li> <li>• Changed dosage to table format (from bullet point)</li> </ul>
13.1 Midazolam		<ul style="list-style-type: none"> <li>• Modified Midazolam dose for sedation when administered intramuscularly to 5 mg for adults</li> </ul>
13.1 Ondansetron (Zofran)	Protocol	<ul style="list-style-type: none"> <li>• Added prolonged QT to contraindications</li> <li>• Added ODT to dosing for patients &gt;4 yo</li> </ul>
13.1 Oxygen (O2)	Protocol	<ul style="list-style-type: none"> <li>• Added use of high flow nasal cannula oxygen therapy when appropriate for intubation</li> </ul>